investing in pharma

JNJ, BioCrossroads invest in Hoosier pharma startup at work on potential hepatitis B cure

An Indiana University spinout attracted investors from Johnson & Johnson Development Corp. and BioCrossroads with novel drugs to treat, and even potentially cure, patients with hepatitis B. Assembly Pharmaceuticals received an undisclosed amount for this seed round. This funding will finance the preclinical proof of concept and help the company establish its bio labs in San Francisco, […]

Emerging sources of early-stage life science funding embrace the role of ‘venture catalysts’

It was nice to hear one healthcare executive and investor after another respond to the question, “what are your key priorities when evaluating a deal?” with the answer, “really compelling science.” I’ve often heard VCs and angel investors cite the importance of large addressable markets and talented executive teams as key considerations to a deal, […]